ADVM - アバランシェ・バイオテクノロジ―ズ （Adverum Biotechnologies Inc.） アバランシェ・バイオテクノロジ―ズADVMのチャート
ADVMの企業情報
| symbol | ADVM |
|---|---|
| 会社名 | Adverum Biotechnologies Inc （アバランシェ・バイオテクノロジ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Adverum Biotechnologies Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research develop and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing specifically in process development and assay development. アバランシェ・バイオテクノロジ―ズは、米国のバイオ医薬品会社。眼科疾患用の新規遺伝子治療薬の発見、開発および商業化に従事。主な製品は、滲出型加齢黄斑変性症の遺伝子治療薬｢AVA-101｣やX染色体連鎖性網膜分離症(XLRS)の遺伝子治療薬｢AVA-311｣。本社は、カリフォルニア州メンロ・パ―ク。 Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. |
| 本社所在地 | 1035 O'Brien Drive Menlo Park CA 94025 USA |
| 代表者氏名 | Paul B. Cleveland ポールB.クリーブランド |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 650-272-6269 |
| 設立年月日 | 38899 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 78人 |
| url | www.avalanchebiotech.com |
| nasdaq_url | https://www.nasdaq.com/symbol/advm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -65.87600 |
| 終値（lastsale） | 5.51 |
| 時価総額（marketcap） | 345444347.74 |
| 時価総額 | 時価総額（百万ドル） 359.86400 |
| 売上高 | 売上高（百万ドル） 1.63300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 124.98800 |
| 当期純利益 | 当期純利益（百万ドル） -54.46500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Adverum Biotechnologies Inc revenues decreased 23% to $709K. Net loss increased 31% to $36M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development -gross increase of 39% to $20.8M (expense) Stock-based Compensation in SGA increase from $1.5M to $6.1M (expense). |
ADVMのテクニカル分析
ADVMのニュース
Adverum Biotechnologies to Present at Upcoming Investor Conferences 2023/02/27 21:05:00 GlobeNewswire
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the following upcoming investor conferences:
Adverum Biotechnologies Inc. (ADVM) will benefit from these strategies 2023/02/24 13:48:00 US Post News
The share price of Adverum Biotechnologies Inc. (NASDAQ:ADVM) rose to $0.70 per share on Thursday from $0.66. While Adverum Biotechnologies Inc. has overperformed by 6.50%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADVM fell by -47.76%, with highs and lows ranging from $1.82 to $0.53, […]
Sector Stocks with Negative Change: Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), Adverum Biotechnologies, Inc. (NASDAQ:ADVM) 2023/02/21 14:42:38 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Sector Stocks with Negative Change: Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), Adverum Biotechnologies, Inc. (NASDAQ:ADVM) appeared first on Stocks Equity .
Was anything negative for Adverum Biotechnologies Inc. (ADVM) stock last session? 2023/02/09 12:40:00 US Post News
The share price of Adverum Biotechnologies Inc. (NASDAQ:ADVM) fell to $0.66 per share on Wednesday from $0.69. While Adverum Biotechnologies Inc. has underperformed by -3.95%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADVM fell by -58.18%, with highs and lows ranging from $1.82 to $0.53, […]
Investing in Adverum Biotechnologies Inc. (ADVM) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/12/28 14:08:00 US Post News
In Tuesday’s session, Adverum Biotechnologies Inc. (NASDAQ:ADVM) marked $0.54 per share, down from $0.57 in the previous session. While Adverum Biotechnologies Inc. has underperformed by -5.26%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADVM fell by -70.17%, with highs and lows ranging from $2.04 to […]
Was anything negative for Adverum Biotechnologies Inc. (ADVM) stock last session? 2023/02/09 12:40:00 US Post News
The share price of Adverum Biotechnologies Inc. (NASDAQ:ADVM) fell to $0.66 per share on Wednesday from $0.69. While Adverum Biotechnologies Inc. has underperformed by -3.95%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADVM fell by -58.18%, with highs and lows ranging from $1.82 to $0.53, […]
Investing in Adverum Biotechnologies Inc. (ADVM) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/12/28 14:08:00 US Post News
In Tuesday’s session, Adverum Biotechnologies Inc. (NASDAQ:ADVM) marked $0.54 per share, down from $0.57 in the previous session. While Adverum Biotechnologies Inc. has underperformed by -5.26%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADVM fell by -70.17%, with highs and lows ranging from $2.04 to […]
Adverum Biotechnologies Inc. (ADVM) did well last session? 2022/12/21 14:08:00 US Post News
Adverum Biotechnologies Inc. (NASDAQ:ADVM) closed Tuesday at $0.57 per share, down from $0.59 a day earlier. While Adverum Biotechnologies Inc. has underperformed by -2.91%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADVM fell by -69.20%, with highs and lows ranging from $2.04 to $0.59, whereas […]
Former Merck Commercial President Dawn Svoronos joins ACELYRIN, INC. Board of Directors 2022/12/13 12:00:00 Kwhen Finance
Can you still get a good price for Adverum Biotechnologies Inc. (ADVM) Shares at this point? 2022/12/01 15:08:00 US Post News
In Wednesday’s session, Adverum Biotechnologies Inc. (NASDAQ:ADVM) marked $0.67 per share, down from $0.68 in the previous session. While Adverum Biotechnologies Inc. has underperformed by -1.50%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADVM fell by -61.50%, with highs and lows ranging from $2.04 to […]
Can you still get a good price for Adverum Biotechnologies Inc. (ADVM) Shares at this point? 2022/12/01 15:08:00 US Post News
In Wednesday’s session, Adverum Biotechnologies Inc. (NASDAQ:ADVM) marked $0.67 per share, down from $0.68 in the previous session. While Adverum Biotechnologies Inc. has underperformed by -1.50%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADVM fell by -61.50%, with highs and lows ranging from $2.04 to […]
Adverum Biotechnologies Inc. (ADVM) Has Great Growth Outlook For 2022 2022/11/23 14:30:00 Marketing Sentinel
Adverum Biotechnologies Inc. (NASDAQ:ADVM) has a beta value of 1.09 and has seen 5.9 million shares traded in the last trading session. The company, currently valued at $67.97M, closed the last trade at $0.69 per share which meant 0.43% during that session. The ADVM stock price is -197.1% off its 52-week high price of $2.05 … Adverum Biotechnologies Inc. (ADVM) Has Great Growth Outlook For 2022 Read More »
Adverum Biotechnologies Inc. (ADVM) can excel with these strategies 2022/11/23 12:08:00 US Post News
In Tuesday’s session, Adverum Biotechnologies Inc. (NASDAQ:ADVM) marked $0.69 per share, up from $0.69 in the previous session. While Adverum Biotechnologies Inc. has overperformed by 0.43%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADVM fell by -64.59%, with highs and lows ranging from $2.05 to […]